Nature Reviews Drug Discovery 16, 755–772 (2017)
In the original version, navitoclax was incorrectly referred to as an apoptosis inhibitor in Figure 3. The error has been corrected online.
Additional information
The online version of the original article can be found at 10.1038/nrd.2017.170
Rights and permissions
About this article
Cite this article
Mora, A., Rojas, M., Pardo, A. et al. Erratum: Emerging therapies for idiopathic pulmonary fibrosis, a progressive age-related disease. Nat Rev Drug Discov 16, 810 (2017). https://doi.org/10.1038/nrd.2017.225
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd.2017.225
This article is cited by
-
Triptolide with hepatotoxicity and nephrotoxicity used in local delivery treatment of myocardial infarction by thermosensitive hydrogel
Journal of Nanobiotechnology (2023)
-
Mangiferin relieves CCl4-induced liver fibrosis in mice
Scientific Reports (2023)
-
Quercetin influences intestinal dysbacteriosis and delays alveolar epithelial cell senescence by regulating PTEN/PI3K/AKT signaling in pulmonary fibrosis
Naunyn-Schmiedeberg's Archives of Pharmacology (2023)
-
The novel role of ER protein TXNDC5 in the pathogenesis of organ fibrosis: mechanistic insights and therapeutic implications
Journal of Biomedical Science (2022)
-
Upregulation of ACE2 and TMPRSS2 by particulate matter and idiopathic pulmonary fibrosis: a potential role in severe COVID-19
Particle and Fibre Toxicology (2021)
